Statements (29)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
gptkb:monoclonal_antibody |
| gptkbp:administeredBy |
intravenous infusion
|
| gptkbp:approvalYear |
2016
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
gptkb:R03DX08
|
| gptkbp:brand |
gptkb:Cinqair
|
| gptkbp:CASNumber |
gptkb:146612-99-9
|
| gptkbp:developer |
gptkb:Teva_Pharmaceutical_Industries
|
| gptkbp:hasMolecularFormula |
C6468H9956N1714O2026S46
|
| https://www.w3.org/2000/01/rdf-schema#label |
reslizumab
|
| gptkbp:indication |
gptkb:eosinophilic_asthma
|
| gptkbp:KEGGID |
D10541
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
gptkb:IL-5_antagonist
|
| gptkbp:molecularWeight |
147 kDa
|
| gptkbp:monoclonalAntibodyType |
humanized
|
| gptkbp:pregnancyCategory |
N (Not classified)
|
| gptkbp:PubChem_CID |
gptkb:CHEMBL1743027
gptkb:DB06287 |
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
muscle pain
anaphylaxis oropharyngeal pain |
| gptkbp:target |
gptkb:interleukin-5
|
| gptkbp:UNII |
6U8Z385M6Z
|
| gptkbp:usedFor |
asthma
|
| gptkbp:bfsParent |
gptkb:IL5
|
| gptkbp:bfsLayer |
6
|